samedan logo
 
 
 
spacer
home > ebr > autumn 2009 > investigating interactions
PUBLICATIONS
European Biopharmaceutical Review

Investigating Interactions

 

As a result of scientific efforts over the last few decades, the Protein Data Bank (PDB) library now contains descriptions of more than 48,000 high-resolution biomolecular structures (1). In addition, characterisation data for more than 38,000 of the estimated 300,000 protein-protein interactions in humans has been collected (2). This information is critical to our understanding of interactions between proteins and in the investigation of the effects of these interactions, from academic research to drug discovery and development. Based on the report by Prasad et al, it can be calculated that only around six per cent of the identified interactions have been confirmed in vivo and with the use of several in vitro techniques (2). Thus, although a significant number of interactions are already well-characterised, there is still a need for additional experimental verification.

As well as the need for investigation of protein structure-function relationships and the mapping of the interactome to increase our biological understanding, there is also a growing demand from regulatory authorities to employ orthogonal approaches to biotherapeutic discovery and development. Complementary methods are needed to enable researchers to validate and verify interaction data, and to make confident conclusions and decisions in the drug development process.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Thomas Lundbäck is a Senior Project Manager at GE Healthcare, Life Sciences. He recently joined GE Healthcare from Biovitrum, where he held the positions of project leader and principal scientist, implementing different biophysical techniques. Thomas has a PhD in biophysical chemistry from the Karolinska Institute in Stockholm, Sweden. He is also a member of the Industrial Research Committee at the Royal Swedish Academy of Engineering Sciences (IVA), which represents research areas of future strategic interest for Swedish industry.
spacer
Thomas Lundbäck
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Brooks Introduces Azenta Life Sciences To Advance Innovative Sample Solutions

CHELMSFORD, Mass., Sept. 28, 2021 -- Today Brooks Automation, Inc. (Nasdaq: BRKS) announces Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences ("Azenta").
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement